Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Blumenthal

Showing results (591-600 of 650) with videos related to

Pageof 65
Sort By:
Nature Communications|August 24, 2016
Global threats from invasive alien species in the twenty-first century and national response capacitiesRegan Early, Bethany A Bradley, Jeffrey S Dukes, et al.
The Oncologist|December 16, 2017
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M MutationLauretta Odogwu, Luckson Mathieu, Kirsten B Goldberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2016
FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following CrizotinibErin Larkins, Gideon M Blumenthal, Huanyu Chen, et al.
Clinical Lung Cancer|March 24, 2020
Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working GroupPatrick M Forde, Phil Bonomi, Alice Shaw, et al.
JCO Precision Oncology|September 11, 2020
Weighing the Evidence: Variant Classification and Interpretation in Precision Oncology, US Food and Drug Administration Public Workshop-Workshop ProceedingsHisani N Horne, Donna Roscoe, E David Litwack, et al.
Ecological Applications : a Publication of the Ecological Society of America|March 20, 2014
Integrated assessment of biological invasionsInes Ibáñez, Jeffrey M Diez, Luke P Miller, et al.
Journal of Medicinal Chemistry|December 29, 2022
Systematic Design of Adenosine Analogs as Inhibitors of a <i>Clostridioides difficile-</i>Specific DNA Adenine Methyltransferase Required for Normal Sporulation and PersistenceJujun Zhou, John R Horton, Martina Menna, et al.
Allergy|January 1, 1996
Tilarin in combination with astemizoleD A Bukstein, R M Biondi, M M Blumenthal, et al.
Journal of Bacteriology|July 27, 2000
AnkB, a periplasmic ankyrin-like protein in Pseudomonas aeruginosa, is required for optimal catalase B (KatB) activity and resistance to hydrogen peroxideM L Howell, E Alsabbagh, J F Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2018
FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast CancerLynn J Howie, Nancy S Scher, Laleh Amiri-Kordestani, et al.
Pageof 65

Showing results (591-600 of 650) with videos related to

Sort By:
Pageof 65
Nature Communications|August 24, 2016
Global threats from invasive alien species in the twenty-first century and national response capacitiesRegan Early, Bethany A Bradley, Jeffrey S Dukes, et al.
The Oncologist|December 16, 2017
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M MutationLauretta Odogwu, Luckson Mathieu, Kirsten B Goldberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2016
FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following CrizotinibErin Larkins, Gideon M Blumenthal, Huanyu Chen, et al.
Clinical Lung Cancer|March 24, 2020
Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working GroupPatrick M Forde, Phil Bonomi, Alice Shaw, et al.
JCO Precision Oncology|September 11, 2020
Weighing the Evidence: Variant Classification and Interpretation in Precision Oncology, US Food and Drug Administration Public Workshop-Workshop ProceedingsHisani N Horne, Donna Roscoe, E David Litwack, et al.
Ecological Applications : a Publication of the Ecological Society of America|March 20, 2014
Integrated assessment of biological invasionsInes Ibáñez, Jeffrey M Diez, Luke P Miller, et al.
Journal of Medicinal Chemistry|December 29, 2022
Systematic Design of Adenosine Analogs as Inhibitors of a <i>Clostridioides difficile-</i>Specific DNA Adenine Methyltransferase Required for Normal Sporulation and PersistenceJujun Zhou, John R Horton, Martina Menna, et al.
Allergy|January 1, 1996
Tilarin in combination with astemizoleD A Bukstein, R M Biondi, M M Blumenthal, et al.
Journal of Bacteriology|July 27, 2000
AnkB, a periplasmic ankyrin-like protein in Pseudomonas aeruginosa, is required for optimal catalase B (KatB) activity and resistance to hydrogen peroxideM L Howell, E Alsabbagh, J F Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2018
FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast CancerLynn J Howie, Nancy S Scher, Laleh Amiri-Kordestani, et al.
Pageof 65